Annual report
4820.TEDINET S100VISF
Period2024-01-01 → 2024-12-31
Filed2025-03-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 186
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥20.4bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥16.9bn | 2022-01-01 → 2022-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.4bn | 2021-01-01 → 2021-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.7bn | 2020-01-01 → 2020-12-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥14.0bn | 2019-01-01 → 2019-12-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.5bn | 2024-01-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2023-01-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥5.2bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.9bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.8bn | 2022-01-01 → 2022-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.6bn | 2021-01-01 → 2021-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.5bn | 2020-01-01 → 2020-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2019-01-01 → 2019-12-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.7bn | 2024-01-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.8bn | 2023-01-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.4bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2022-01-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.8bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.1bn | 2020-01-01 → 2020-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2019-01-01 → 2019-12-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.4bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | ¥2.0bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥31.7bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥29.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥26.3bn | at 2022-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.8bn | at 2021-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥23.1bn | at 2020-12-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥23.4bn | at 2019-12-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.1bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥8.8bn | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥20.6bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥20.6bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥19.5bn | at 2022-12-31d | Cons. | Net assets |
| Net assets / equity | ¥18.8bn | at 2021-12-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥17.7bn | at 2020-12-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥17.7bn | at 2019-12-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.9bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥11.9bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.9bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥8.3bn | at 2021-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.0bn | at 2020-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.8bn | at 2019-12-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥5.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥442m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.3bn | 2019-01-01 → 2019-12-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥194m | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥577m | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥544m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥147m | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥343m | 2019-01-01 → 2019-12-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3.6bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥993m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2022-01-01 → 2022-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥693m | 2021-01-01 → 2021-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2020-01-01 → 2020-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥668m | 2019-01-01 → 2019-12-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥34.54 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.76 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.75 | 2022-01-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.72 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.95 | 2020-01-01 → 2020-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.74 | 2019-01-01 → 2019-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥34.43 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.68 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.66 | 2022-01-01 → 2022-12-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥25.64 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥14.88 | 2020-01-01 → 2020-12-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥19.47 | 2019-01-01 → 2019-12-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥297.04 | at 2024-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥289.47 | at 2023-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥274.94 | at 2022-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥263.12 | at 2021-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥248.55 | at 2020-12-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥247.51 | at 2019-12-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 64.8% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.6% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.7% | at 2022-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.5% | at 2021-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.4% | at 2020-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.1% | at 2019-12-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 11.8% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.8% | 2023-01-01 → 2023-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.9% | 2022-01-01 → 2022-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2020-01-01 → 2020-12-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2019-01-01 → 2019-12-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 827 | at 2024-12-31 | Cons. | Number of employees |
| Employees | 811 | at 2023-12-31 | Cons. | Number of employees |
| Employees | 592 | at 2022-12-31d | Cons. | Number of employees |
| Employees | 558 | at 2021-12-31d | Cons. | Number of employees |
| Employees | 557 | at 2020-12-31d | Cons. | Number of employees |
| Employees | 575 | at 2019-12-31d | Cons. | Number of employees |
| Revenue | ¥19.9bn | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥17.3bn | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥16.1bn | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥13.6bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.9bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥12.3bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥3.7bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | ¥1.7bn | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | ¥4.5bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.4bn | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.8bn | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.5bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.0bn | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.0bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.4bn | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income | ¥2.0bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥1.7bn | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | ¥2.0bn | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.0bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥894m | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.3bn | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥28.3bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥26.4bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥25.2bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥23.9bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.6bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥22.1bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥8.8bn | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥6.7bn | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥19.5bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥19.7bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥19.0bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥18.2bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥16.8bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥16.9bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥8.3bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.9bn | at 2023-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥28.06 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.12 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.79 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.6 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥12.59 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.44 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.97 | 2024-01-01 → 2024-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.04 | 2023-01-01 → 2023-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥27.71 | 2022-01-01 → 2022-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥28.51 | 2021-01-01 → 2021-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥12.53 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥18.19 | 2019-01-01 → 2019-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥35 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2023-01-01 → 2023-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2022-01-01 → 2022-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2020-01-01 → 2020-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2019-01-01 → 2019-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥281.91 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥278.05 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥267.83 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥255.16 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥235.28 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥236.71 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 68.8% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.5% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.0% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.1% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.4% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.1% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.1% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2023-01-01 → 2023-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.6% | 2022-01-01 → 2022-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.7% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.3% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2019-01-01 → 2019-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 70,514,800 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 74,514,800 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 74,514,800 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 74,514,800 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 74,514,800 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 74,063,600 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 497 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 457 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 432 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 413 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 418 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 448 | at 2019-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 84
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-12-31 | 73 pure |
| Otherother segments | capex | 2024-01-01 → 2024-12-31 | ¥0 |
| Otherother segments | depreciation | 2024-01-01 → 2024-12-31 | ¥16m |
| Otherother segments | revenue | 2024-01-01 → 2024-12-31 | ¥1.2bn |
| Otherother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥1.0bn |
| Otherother segments | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥152m |
| Otherother segments | segment assets | at 2024-12-31 | ¥1.0bn |
| Otherother segments | segment profit | 2024-01-01 → 2024-12-31 | ¥60m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥198m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥171m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥171m |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥19.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | ¥22m |
| Care Welfare IT Systems Businessreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥381m |
| Care Welfare IT Systems Businessreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥171m |
| Care Welfare IT Systems Businessreportable segment | employees | at 2024-12-31 | 59 pure |
| Care Welfare IT Systems Businessreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥570m |
| Care Welfare IT Systems Businessreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥570m |
| Care Welfare IT Systems Businessreportable segment | segment assets | at 2024-12-31 | ¥141m |
| Care Welfare IT Systems Businessreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥450m |
| Medecl Computerreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥115m |
| Medecl Computerreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥193m |
| Medecl Computerreportable segment | employees | at 2024-12-31 | 173 pure |
| Medecl Computerreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥2.6bn |
| Medecl Computerreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥2.6bn |
| Medecl Computerreportable segment | segment assets | at 2024-12-31 | ¥797m |
| Medecl Computerreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥423m |
| Pharmacy Receipt Computerreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥627m |
| Pharmacy Receipt Computerreportable segment | depreciation | 2024-01-01 → 2024-12-31 | ¥774m |
| Pharmacy Receipt Computerreportable segment | employees | at 2024-12-31 | 473 pure |
| Pharmacy Receipt Computerreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥20.7bn |
| Pharmacy Receipt Computerreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥20.7bn |
| Pharmacy Receipt Computerreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥19m |
| Pharmacy Receipt Computerreportable segment | segment assets | at 2024-12-31 | ¥9.9bn |
| Pharmacy Receipt Computerreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥5.3bn |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥1.1bn |
| —segment total | depreciation | 2024-01-01 → 2024-12-31 | ¥1.2bn |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥25.0bn |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥24.8bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥171m |
| —segment total | segment assets | at 2024-12-31 | ¥11.8bn |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | ¥4.4bn |
| Otherother segments | capex | 2023-01-01 → 2023-12-31 | ¥0 |
| Otherother segments | depreciation | 2023-01-01 → 2023-12-31 | ¥4m |
| Otherother segments | revenue | 2023-01-01 → 2023-12-31 | ¥973m |
| Otherother segments | revenue external | 2023-01-01 → 2023-12-31 | ¥860m |
| Otherother segments | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥112m |
| Otherother segments | segment assets | at 2023-12-31 | ¥876m |
| Otherother segments | segment profit | 2023-01-01 → 2023-12-31 | ¥48m |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | −¥20m |
| Reconciling Itemsreconciling | depreciation | 2023-01-01 → 2023-12-31 | ¥200m |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-12-31 | −¥131m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-12-31 | −¥131m |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥17.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | ¥13m |
| Care Welfare IT Systems Businessreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥175m |
| Care Welfare IT Systems Businessreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥153m |
| Care Welfare IT Systems Businessreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥550m |
| Care Welfare IT Systems Businessreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥550m |
| Care Welfare IT Systems Businessreportable segment | segment assets | at 2023-12-31 | ¥902m |
| Care Welfare IT Systems Businessreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥540m |
| Medecl Computerreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥83m |
| Medecl Computerreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥203m |
| Medecl Computerreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥2.8bn |
| Medecl Computerreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥2.8bn |
| Medecl Computerreportable segment | segment assets | at 2023-12-31 | ¥1.2bn |
| Medecl Computerreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥130m |
| Pharmacy Receipt Computerreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥3.2bn |
| Pharmacy Receipt Computerreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥687m |
| Pharmacy Receipt Computerreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥16.2bn |
| Pharmacy Receipt Computerreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥16.1bn |
| Pharmacy Receipt Computerreportable segment | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥18m |
| Pharmacy Receipt Computerreportable segment | segment assets | at 2023-12-31 | ¥9.1bn |
| Pharmacy Receipt Computerreportable segment | segment profit | 2023-01-01 → 2023-12-31 | ¥2.9bn |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥3.4bn |
| —segment total | depreciation | 2023-01-01 → 2023-12-31 | ¥1.0bn |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥20.5bn |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥20.4bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-12-31 | ¥131m |
| —segment total | segment assets | at 2023-12-31 | ¥12.2bn |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | ¥2.3bn |
| Care Welfare IT Systems Businessreportable segment | employees | at 2024-12-31 | 38 pure |
| Medecl Computerreportable segment | employees | at 2024-12-31 | 133 pure |
| Pharmacy Receipt Computerreportable segment | employees | at 2024-12-31 | 288 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,659
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cf | CurrentYearDuration | -316000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | － | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -999000000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -1060000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -1123000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | 993000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -3567000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 20000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 59000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 560000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 2442000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 8881000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 9441000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 9441000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 11884000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 8 | |
| Notes receivable trade | Prior1YearInstant | 53000000 | JPY |
| Notes receivable trade | CurrentYearInstant | 78000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 3029000000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 4215000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 8000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 13000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05155-000PharmacyReceiptComputerReportableSegmentsMember | 16140000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05155-000MedeclComputerReportableSegmentsMember | 2802000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05155-000CareWelfareITSystemsBusinessReportableSegmentsMember | 550000000 | JPY |
| Revenues from external customers | Prior1YearDuration_OtherReportableSegmentsMember | 860000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 20355000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 20355000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05155-000PharmacyReceiptComputerReportableSegmentsMember | 18000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05155-000MedeclComputerReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05155-000CareWelfareITSystemsBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_OtherReportableSegmentsMember | 112000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 131000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -131000000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05155-000PharmacyReceiptComputerReportableSegmentsMember | 16159000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05155-000MedeclComputerReportableSegmentsMember | 2802000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05155-000CareWelfareITSystemsBusinessReportableSegmentsMember | 550000000 | JPY |
| Net sales | Prior1YearDuration_OtherReportableSegmentsMember | 973000000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 20487000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -131000000 | JPY |
| Net sales | Prior1YearDuration | 20355000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05155-000PharmacyReceiptComputerReportableSegmentsMember | 2939000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05155-000MedeclComputerReportableSegmentsMember | -130000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E05155-000CareWelfareITSystemsBusinessReportableSegmentsMember | -540000000 | JPY |
| Operating income | Prior1YearDuration_OtherReportableSegmentsMember | 48000000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | 2316000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | 13000000 | JPY |
| Operating income | Prior1YearDuration | 2330000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |